Hydrogel Arrays Enable Increased Throughput for Screening Effects of Matrix Components and Therapeutics in 3D Tumor Models

Summary

The present protocol describes an experimental platform to assess the effects of mechanical and biochemical cues on chemotherapeutic responses of patient-derived glioblastoma cells in 3D matrix-mimetic cultures using a custom-made UV illumination device facilitating high-throughput photocrosslinking of hydrogels with tunable mechanical features.

Abstract

Cell-matrix interactions mediate complex physiological processes through biochemical, mechanical, and geometrical cues, influencing pathological changes and therapeutic responses. Accounting for matrix effects earlier in the drug development pipeline is expected to increase the likelihood of clinical success of novel therapeutics. Biomaterial-based strategies recapitulating specific tissue microenvironments in 3D cell culture exist but integrating these with the 2D culture methods primarily used for drug screening has been challenging. Thus, the protocol presented here details the development of methods for 3D culture within miniaturized biomaterial matrices in a multi-well plate format to facilitate integration with existing drug screening pipelines and conventional assays for cell viability. Since the matrix features critical for preserving clinically relevant phenotypes in cultured cells are expected to be highly tissue- and disease-specific, combinatorial screening of matrix parameters will be necessary to identify appropriate conditions for specific applications. The methods described here use a miniaturized culture format to assess cancer cell responses to orthogonal variation of matrix mechanics and ligand presentation. Specifically, this study demonstrates the use of this platform to investigate the effects of matrix parameters on the responses of patient-derived glioblastoma (GBM) cells to chemotherapy.

Introduction

The expected cost of developing a new drug has steadily risen over the past decade, with over $1 billion in current estimates¹. Part of this expense is the high failure rate of drugs entering clinical trials. Approximately 12% of drug candidates ultimately earn approval from the United States (US) Food & Drug Administration (FDA) in 2019. Many drugs fail in Phase I due to unanticipated toxicity², while others that pass safety trials may fail due to a lack of efficacy³. This attrition due to non-efficacy can partly be explained by the fact that cancer models used during drug development are notoriously non-predictive of clinical efficacy⁴.

Functional disparities between in vitro and in vivo models may be attributed to removing cancer cells from their native microenvironment, including non-tumor cells and the physical ECM^5,6. Commonly, research groups use commercially available culture matrices, such as Matrigel (a proteinaceous basement membrane matrix derived from mouse sarcomas) to provide cultured tumor cells with a 3D matrix microenvironment. Compared to 2D culture, 3D culture in membrane matrix has improved the clinical relevance of in vitro results^7,8. However, culture biomaterials from decellularized tissues, including the membrane matrix, typically exhibit batch-to-batch variability that may compromise reproducibility⁹. Furthermore, matrices derived from tumors with different tissue origins from those studied may not provide the appropriate physiological cues¹⁰. Finally, cancers with high degrees of intratumoral heterogeneity have microenvironmental features that vary on a submicron-size scale and which the membrane matrix cannot be tuned to recapitulate¹¹.

Glioblastoma (GBM), a uniformly lethal brain tumor with a median survival time of approximately 15 months, is a cancer for which treatment development has been particularly difficult^12,13. The current standard of care for GBM consists of primary tumor resection, followed by radiotherapy, and then chemotherapy using temozolomide (TMZ)¹⁴. Yet, more than half of clinical GBM tumors exhibit treatment resistance through various mechanisms^15,16,17. Predicting the efficacy of a treatment regimen for an individual patient is extremely difficult. Standard preclinical models used to predict individual outcomes consist of patient-derived tumor cells xenografted orthotopically into immunocompromised mice. While patient-derived xenografts can recapitulate many aspects of clinical GBM tumors and are valuable for preclinical models¹⁸, they are inherently expensive, low throughput, time-consuming, and involve ethical concerns¹⁹. Cultures of patient-derived cells, on 2D plastic surfaces or as spheroids, mostly avoid these issues. While patient-derived cells preserve genetic aberrations, their cultures in 2D or as suspended spheroids have been largely poor representations of patient-derived xenografts in rodents and original patient tumors²⁰. Previously, we, and others, have shown that GBM cells cultured in a 3D ECM that mimics the mechanical and biochemical properties of brain tissue can preserve drug resistance phenotypes^10,21,22,23.

Interactions between hyaluronic acid (HA), a polysaccharide abundant in the brain ECM and overexpressed in GBM tumors, and its CD44 receptor modulate the acquisition of drug resistance in vitro^{21,24,25,26,27}. For example, the inclusion of HA within soft, 3D cultures increased the ability of patient-derived GBM cells to acquire therapeutic resistance. This mechano-responsivity was dependent on HA binding to CD44 receptors on GBM cells²¹. Additionally, integrin binding to RGD-bearing peptides, incorporated into 3D culture matrices, amplified CD44-mediated chemoresistance in a stiffness-dependent manner²¹. Beyond HA, the expression of several ECM proteins, many containing RGD regions, vary between normal brain and GBM tumors²⁸. For example, one study reported that 28 distinct ECM proteins were upregulated in GBM tumors²⁹. Within this complex tumor matrix microenvironment, cancer cells integrate mechanical and biochemical cues to yield a particular resistance phenotype, which depends on relatively small differences (e.g., less than an order of magnitude) in Young's modulus or density of integrin-binding peptides^28,29,30.

The present protocol characterizes how tumor cells interpret unique combinations of matrix cues and identify complex, patient-specific matrix microenvironments that promote treatment resistance (Figure 1A). A photochemical method for generating miniaturized, precisely tuned matrices for 3D culture provides a large, orthogonal variable space. A custom-built array of LEDs, run by a microcontroller, was incorporated to photocrosslink hydrogels within a 384-well plate format to increase automation and reproducibility. Exposure intensity was varied across well to alter micro-mechanical properties of resulting hydrogels, as assessed using atomic force microscopy (AFM). While this manuscript does not focus on constructing the illumination array itself, a circuit diagram (Figure 1B) and parts list (Table of Materials) are provided as aids for device reproduction.

This report demonstrates the rapid generation of an array of GBM cells cultured in unique, 3D microenvironments in which Young's modulus (four levels across a single order of magnitude) and integrin-binding peptide content (derived from four different ECM proteins) were varied orthogonally. The approach was then used to investigate the relative contributions of hydrogel mechanics and ECM-specific integrin engagement on the viability and proliferation of patient-derived GBM cells as they acquire resistance to temozolomide (TMZ) chemotherapy.

Protocol

Patient-derived GBM cell lines (GS122 and GS304) were provided by Professor David Nathanson (our collaborator), who developed these lines under a protocol approved by the UCLA Institutional Review Board (IRB# 10-000655). Cells were provided de-identified so that the cell lines could not be linked back to the individual patients.

1. Preparation of hydrogel solution

1. Prepare HEPES-buffered solution by dissolving HEPES powder at 20 mM in Hank's balanced salt solution (HBSS). Adjust pH to 7 following full solvation.
2. In the HEPES-buffered solution, dissolve thiolated HA (700 kDa nominal molecular weight, see Table of Materials), prepared following the previous report³¹, so that 6%-8% of carboxylic acid residues on each glucuronic acid are modified with a thiol, at a concentration of 10 mg/mL in buffer solution.
   NOTE: An amber vial is recommended to prevent thiol oxidation by ambient light.
   1. Stir using a magnetic stir plate (<1,000 rpm) at room temperature until fully dissolved, typically around 45 min.
3. While HA is dissolving, prepare separate solutions of (1) 100 mg/mL of 8-arm-PEG-Norbornene (20 kDa), (2) 100 mg/mL of 4-arm-PEG-Thiol (20 kDa), (3) 4 mM of cysteine or cysteine-containing peptide (e.g., GCGYGRGDSPG), and (4) 4 mg/mL of LAP in microcentrifuge tubes (see Table of Materials).
   1. Prepare each of these four solutions in the HEPES-buffered solution prepared in step 1.1. Vortex the solutions to ensure full dissolution of each reagent prior to performing step 4.
      NOTE: If testing multiple different peptides, each must contain a cysteine or other source of thiol moiety for this conjugation chemistry.
   2. Prepare solutions (4 mM available thiol) of all peptides to be tethered within a single hydrogel at this point.
      NOTE: Peptide sequences and ECM proteins from which they were derived and used in this study are listed in Table 1. N-acetyl cysteine (see Table of Materials), to which cells do not bind, can be substituted for a bioactive, thiol-containing peptide to titrate the concentration of an adhesive peptide or act as a negative control³¹.
4. Mix the individual solutions of HA, PEG-Norbornene, PEG-thiol, and cysteine/thiol-containing peptides (see Table of Materials) to achieve the final concentrations for the final hydrogel matrices listed in Table 2. Stir (<1,000 rpm) on a magnetic stir plate for at least 30 min to mix fully.
   ​NOTE: HA solutions are highly viscous and best handled using a positive displacement pipette (see Table of Materials). If a positive displacement pipette is unavailable, viscous solutions can also be dispensed with a standard micropipette by slowly pipetting using wide-orifice tips.

2. Illumination and photocrosslinking of hydrogels via an LED array

CAUTION: Wear UV protective eyewear and cover the illumination field with UV-absorbing material.

NOTE: The LED array described in this protocol consists of six sets of eight LEDs placed in series, as illustrated by the provided circuit diagram (Figure 1A). Each set of LEDs can be independently powered, which allows for up to six different irradiances per run. Supplementary File 1 contains screenshots corresponding to the following directions for further guidance.

1. Download the Illumination Device.zip file from the Supplementary Coding Files. This directory contains the following files: Arduino.zip (Supplementary Coding File 1), Drivers.zip (Supplementary Coding File 2), GUI.zip (Supplementary Coding File 3), and Holder.zip (Supplementary Coding File 4).
   NOTE: 3D Print the top and bottom portions for holding the circuit board in place (see Supplementary Coding Files for details).
2. Download and install the microcontroller software (see Table of Materials).
3. Download and install the GUI software (see Table of Materials). Refer to Supplementary File 1 for software operating instructions.
4. Open Processing and install the controlIP5 library via clicking on Sketch > Import Library > Add Library. Then, search for controlIP5 in libraries and click on Install. Perform this for the very first time.
5. Power the illumination device (see Table of Materials) using the 36 Volt power supply and connect it to a PC using a micro-USB cable.
   NOTE: Some devices will not install drivers automatically for various Arduino nano boards. One set of drivers is provided in the device zip file.
6. Open the Arduino.ino file, located in the Adruino.zip folder, using Arduino IDE.
7. Compile the Arduino.ino file by clicking on the Checkmark button. Upload the compiled code by clicking on the Arrow button.
8. Open the GUI.pde file, located in the GUI.zip folder, using Processing.
9. Click on Run in the processing program to launch the graphical user interface for controlling the illumination device.
10. In the graphical user interface window, click on Intensity for the column containing hydrogel precursor solution to be crosslinked and input the desired intensity. Click on the Time box and input desired time. For the solution provided in Table 2, this will be 15 s.
    NOTE: End-users need to calibrate digital intensity values to irradiance using a radiometer. Examples of typical intensities are provided in Figure 2A.
11. Align the samples with the illumination device (Figure 2B) with every other LED in a single column of the silicone molds (see Table of Materials) or 384-well plate. Click on Finish to begin illumination. Repeat this process as necessary for illumination of multiple slides or other wells of a 384-well plate.
    NOTE: The holder is designed such that the 384-well plate sits flush with one corner of the inner chamber during illumination.
    1. Following illumination, when placed in one corner, move the well plate to the next corner and repeat. To illuminate wells on the other half of the plate, lift the plate out of the holder and rotate 180°.
12. Generate hydrogels with varying mechanics for mechanical characterization following the steps below.
    1. Clean the glass slides and silicone molds using tape to remove debris. Adhere the silicone molds to the glass slide, press down to ensure a good seal, and displace any air bubbles.
    2. Pipette 80 µL of hydrogel precursor solution, as prepared in step 1.4, into each silicone mold on the glass slide.
    3. Place the glass slide onto the illumination device aligned with every other LED in a single column. Expose the hydrogel precursors to UV light for 15 s, as described in step 2, to photocrosslink.
    4. Once illumination has stopped, retrieve the slides, and loosen the gels from the molds by tracing the inner circumference of the mold with a fine tip (10 µL pipette tip, 30 G needle, etc.). Remove silicone molds with tweezers/forceps.
    5. Move crosslinked hydrogels into individual wells of a 12-well plate by wetting a spatula and gently pushing them off the glass slide. Fill each well with 2 mL of DPBS (see Table of Materials) prior to adding the hydrogel. Swell the gels in DPBS solution for at least 12 h (typically overnight) at room temperature (for the next day's mechanical characterization).

3. Atomic Force Microscopy (AFM) measurements

1. Turn on the atomic force microscope (AFM) according to the manufacturer's instructions (see Table of Materials). This protocol provides brief instructions for using the instrument and the related software.
2. Install the AFM probe (see Table of Materials).
   NOTE: For the present study, a triangular silicon nitride cantilever with a nominal spring constant of 0.01 N/m was modified with a spherical 2.5 µm silicon dioxide particle.
3. Following installation, align the laser to the apex of the triangular probe, and then adjust mirror and laser deflection to maximize signal sum (typically between 1.5-2.2 Volts).
4. Immerse the probe in DPBS and wait for up to 15 min to obtain thermal equilibrium. Click on the Calibration button and select Contact-Dependent calibration. Click on the Collect Thermal Tuning button, and following data collection, select the peak around 3 kHz for calibration.
   NOTE: Slight adjustment of the mirror and laser deflectors may be necessary following immersion into a liquid due to refractive index changes.
5. Approach the surface of a Petri dish (plastic) by setting the Approach Parameters to Constant Velocity, a target height of 7.5 µm, and an approach speed of 15 µm/s. Enable Baseline Measurement Per Run for Approach so that the approach runs continuously and does not stop early due to drift in the deflector.
6. Upon approach, set acquisition parameters for force mapping to 4 nN turnarounds, 2 µm indentation distance, 1 µm/s velocity, and 0 s contact time. Press the Start button to begin collecting a force curve on the plastic surface (e.g., a well plate).
7. Return to the calibration window and select the portion of the force curve corresponding to contact and indentation of the plastic. Accept the calculated sensitivity and stiffness values for the probe to complete calibration.
8. Following calibration, raise the AFM probe and place the hydrogel sample for interrogation. Approach hydrogel following the settings provided in step 5.
   NOTE: During the approach procedure toward the hydrogel surface, the unit may mistakenly trigger the approached state. To verify the actual approach, obtain a force curve as in step 4.6. Repeat the approach procedure if the resulting curve does not show contact and resulting indentation.
9. When the surface approach is successful, switch to the Force Mapping mode and set acquisition parameters to a map of 8 x 8 size with 40 µm length per axis. Obtain force maps in various regions to assess the uniformity of stiffness measurements.
   1. Interpret force curves using the software program JPK SPM Data Processing through a Hertz/Sneddon model fit (Equations 1 and 2, see Table 3 for the definition of all the variables) with the spherical geometry selected^32,33,34.
         Equation 1³²
         Equation 2³²

4. Setting up and drug treatment of 3D, matrix-embedded cultures

1. Prepare desired cells as a single cell solution.
   NOTE: Different cell types may require different passaging methods. A typical protocol for passaging a suspension culture of GBM spheroids from a T-75 flask is reported in reference³¹.
2. Collect GBM spheroids (roughly 150 µm in diameter) from a T-75 flask suspension culture into a 15 mL conical tube. Rinse the culture flask with 5 mL of DPBS to remove any residual cells and media and add this volume to the conical tube.
3. Centrifuge the conical tube containing cells at 200 x g for 5 min at room temperature. Following centrifugation, remove the supernatant with a 5 mL serological pipette, taking care not to disturb the cell pellet, and resuspend in 5 mL of DPBS.
4. Centrifuge at 200 x g for 5 min at room temperature to wash cells. Aspirate the supernatant with a 5 mL serological pipette, taking care not to disturb the cell pellet, and then resuspend cells in 2 mL of cell dissociation reagent (see Table of Materials).
5. Incubate at room temperature for 10-15 min. Add 3 mL of complete medium (see Table of Materials) and gently pipette 3-5 times to break down the spheroids to a single cell suspension³¹.
6. Centrifuge the single-cell suspension at 400 x g (single-cell suspensions may be spun faster for pellet formation) for 5 min to pellet cells at room temperature. Aspirate the supernatant with a 5 mL serological pipette, taking care not to disturb the cell pellet. Resuspend cells in 1 mL of complete medium.
   NOTE: If the cells remain in clumps, rather than as single cells in suspension, following passaging, cells can be passed through a 40 µm cell strainer to achieve a single cell suspension.
7. Remove a portion of the cells for counting using a hemocytometer. Dilute this portion two-fold with trypan blue, which permeates cells with compromised viability. Count only the live, colorless cells. Typically, a T-75 seeded at 800,000 cells per flask yields 2-3 million cells after a week in culture.
8. Determine the number of cells necessary for encapsulation. Transfer a volume of media containing the total number of cells needed into a sterile 1.7 mL microcentrifuge tube. Spin down at 400 x g for 5 min at room temperature.
   NOTE: For example, a minimum of 2.5 million cells resuspended in 1 mL of gel volume is needed to encapsulate cells at 2.5 million cells/mL. A gel volume of 1 mL allows users to dispense 100 gel drops, where each gel drop is of 10 µL volume. Preparing an extra ~20% volume of cells suspended in hydrogel solution is recommended to account for loss during pipette transfer. Thus, one would prepare 3 million cells and 1.2 mL of hydrogel precursor solution in this example. A minimum density of 500 thousand cells/mL is recommended.
9. Aspirate the supernatant with a micropipette, taking care not to disturb the cell pellet. Resuspend the cell pellet in the hydrogel precursor solution, as prepared in step 1.4, mixing well by pipetting up and down with a 1,000 µL micropipette 4-5 times.
10. Load the cells into a repeat pipettor (see Table of Materials) set to dispense 10 µL. To avoid bubbles and uneven dispensing, prime the repeat pipettor by dispensing an additional 1-2 times into a waste container.
11. In each well of a 384-well plate, dispense 10 µL of cells suspended in hydrogel solution from the repeat pipettor. Using the LED array, illuminate each well containing cells (step 2) for 15 s with intensities (example results in Figure 2A utilized intensities of 1.14, 1.55, 2.15, 2.74 mW/cm²) to achieve the desired mechanical properties.
    NOTE: It is suggested to start with five replicates per experimental condition and scale up or down depending on the desired throughput and variance of the endpoint assay.
12. Add 40 µL of complete media to each well containing the cells. Add 50 µL of DPBS to non-experimental, dry wells surrounding the gels to minimize losses due to evaporation.
13. For GBM cells, add 40 µL of the media-containing drug (e.g., TMZ, see Table of Materials) to achieve the final desired concentration (10 µM-100 µM in dimethylsulfoxide (DMSO) or vehicle (DMSO), accordingly, starting 3 days after encapsulation.

5. CCK8 proliferation assay

1. Add 10 µL of CCK8 reagent (see Table of Materials) to each well containing the cells.
   NOTE: If performing this assay for the first time, include negative control wells such as media only or cell-free hydrogel in media.
2. Incubate for 1-4 h according to the manufacturer's instructions.
   NOTE: This time may vary as a function of cell type and density, and thus incubation times need to be tested for each application so that absorbance values fall within a linear range, a requirement for applying Beer's Law³⁵.
3. Read absorbances at 450 nm for all wells following incubation.
4. Calculate the average absorbance at 450 nm obtained in step 3 for the vehicle condition for each group. Divide each drug-treated well by the average of the vehicle control per group.
5. Calculate confidence intervals by generating bootstrap distributions (N = 10,000) through the percentile method³⁶.
   NOTE: Generally, one may utilize 95% confidence intervals and interpret conditions whose confidence intervals do not cross over 1 to be significant and warrant further investigation. Setting confidence intervals to 95% is congruent with setting a significance cutoff of p = 0.05. For the data shown in the results, there is utility in distinguishing conditions that either promote or inhibit matrix-mediated drug resistance, requiring a two-side analysis.

Results

AFM measurements confirmed precise control of hydrogel mechanics as a function of UV irradiance (mW/cm²) during photo-crosslinking using a custom-built, Arduino-controlled LED array (Figure 2A). The hydrogel formulation used in this protocol can be found in Table 2. The spacing of the LEDs on the provided template matches the spacing for every other well of a 384-well plate, allowing for the formation of gels inside the plate (Figure 2B

Discussion

The current work presents methods to generate 3D, miniaturized cultures within HA-based while simultaneously altering matrix stiffness and peptides available for integrin engagement. This technique enables the systematic study of how matrix parameters affect cellular phenotypes (e.g., the viability of cancer cells exposed to chemotherapy) with increased throughput. Previous approaches, including that presented herein, have tuned hydrogel stiffness by varying the percent total polymer in the final formulation, where stiff...

Materials

Name	Company	Catalog Number	Comments
1.1 kOhm resistors, 6 W	Digikey	35601k1ft
1.7 mL microcentrifuge tube	Genesse Scientific	21-108
15 mL conical tube	Fisher Scientific	14-959-70C
365 nm LED	Digikey	ltpl-c034uvh365
384 well plate	Bio Greiner One	781090
40 µm cell strainer	MTC bio	C4040
4-Armed thiol terminated polyethlene glycol (20 kDa)	Laysan Bio	4arm-PEG-SH-20K-1g
6 NPN BJTs	Digikey	2n5550ta
80 Ohm resistors, 0.125 W	Digikey	erjj-6enf80r6v
8-Armed norbornene terminated polyethylene glycol (20 kDa)	Jenkem Technology	A7025-1
Accutase	Innovative Cell Technologies	AT104500	cell dissociation  reagent
AFM Probes	Novascan		0.01 N/m Nominal spring constant, 2.5 µm SiO2 particle
Arduino IDE	Arduino	1.8.19
Arduino Nano	Makerfire	Mini Nano V3.0 ATmega328P Microcontroller Board
bFGF	Peprotech	100-18B	20 ng/mL
CCK8	Abcam	ab228554
Centrifuge	Thermoscientific	sorvall legend xtr
CP100ST	Gilson	F148415	Pipette tips for positive displacement pipette
Cubis Semi-Micro Balance	Sartorius	MSA225S100DI
DMEM - F12 (50-50)	Life Technologies	11330057	1x
DMSO	Fisher Scientific	BP231-100
DPBS Ca (-) Mg (-)	Genesse Scientific	25-508
EGF	Peprotech	AF100-15	50 ng/mL
Ethanol, Anhydrous	Fisher Scientific	A405P	Add DI water to dilute to 70%
Fisherbrand Class B Amber Glass threaded vials	Fisher Scientific	03-339-23C
Fisherbrand Weighing Paper	Fisher Scientific	09-898-12B
G21 Supplement	Gemini Bio	400-160	50x
Hanks Balanced Salt Solution	Thermo Fisher Scientific	14175095
HCl, ACS, 12M	Sigma Aldrich	S25838A	Add DI water to dilute to 1 M
Heparin sodium salt from porcine intestinal mucosa	Sigma Aldrich	H3149-100Ku	25 µg/mL
HEPES	Sigma Aldrich	H7006-100G
Hot Air Gun	Wagner	HT1000
Integrin-binding sialoprotein (IBSP) peptide	Genscript	Custom Order	GCGYGGGGNGEPRGDTYRAY
Lithium phenyl-2,4,6 trimethylbenzoylphosphinate (LAP) , >95%	Sigma Aldrich	900889-1G
Magnetic stir plate	Thermo Scientific	SP194715
Microcentrifuge	Thermo Scientific	Sorvall legend micro 21R
Microman E single Channel Pipettor	Gilson	FD10004	Positive displacement pipette
Micropipette Tips	Various Manufacturs		Various sizes
mLine micropipette	Sartorious
N-acetyl Cysteine	Sigma Aldrich	A7250-10G
Nanowizard 4	Bruker		AFM microscope
NaOH	Fisher Scientific	ss255-1	Add DI water to dilute to 1 M
Normoicin	Invivogen	ant-nr-1	500x
Osteopontin Peptide	Genscript	Custom Order	GCGYGTVDVPDGRGDSLAYG
Pipet Aid	Drummond	4000102
Plain Microscope Slides	Globe Scientific	1301
Press-To-Seal silicone Isolator, 12-4.5mm diam x 2mm deep	Grace Bio Labs	664201-A	Cut so that 8 individual molds are made from a single sheet
Processing	Processing	3.5.4
Repeater M4	Eppendorf	4982000322
Repeater Pipette Tips	Sartorious	30089430	1 mL sizes
RGD Peptide	Genscript		GCGYGRGDSPG
Scoth Tape
Serological Pipettes	Genesse Scientific	12-102,12-104	5,10 mL Pipettes
Solder Paste	Digikey	315-NC191LT15T5-ND
Solder Wire
Straight dissecting forceps	VWR Scientific	82027-408
Synergy H1 Plate Reader	Biotek
T-75 Cell Culture Treated Flask	Genesee Scientific	25-209
Temozolomide	Sigma Aldrich	T2577	Typically used from 10 µM to 100 µM
Tenascin-C Peptide	Genscript		GCGYGRSTDLPGLKAATHYTITIR GV
Thiolated Hyaluronic Acid (700 kDa), 6-8% modified	Lifecore Biomedical	HA700K5
VWR Spinbar, Flea Micro	VWR	58948-375